1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Oxytetracycline hydrochloride and hydrocortisone acetate ophthalmic suspension

- Trade Name: Not determined
- Synonyms: Terra-Cortril® ophthalmic suspension
- Chemical Family: Tetracycline derivative/Steroids
- Intended Use: Anti-inflammatory/Anti-infective agent

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytetracycline hydrochloride</td>
<td>2058-46-0</td>
<td>218-161-2</td>
<td>*</td>
</tr>
<tr>
<td>Hydrocortisone acetate</td>
<td>50-03-3</td>
<td>200-004-4</td>
<td>*</td>
</tr>
<tr>
<td>Aluminum stearate</td>
<td>637-12-7</td>
<td>211-279-5</td>
<td>*</td>
</tr>
<tr>
<td>Mineral oil, heavy</td>
<td>8042-47-5</td>
<td>232-455-8</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary

3. HAZARDSD IDENTIFICATION

Appearance: Light yellow suspension
Signal Word: CAUTION

Statement of Hazard:
- Eye Contact: None known
- Skin Contact: Prolonged or repeated contact may cause defatting and drying of the skin.
- Inhalation: None known
- Ingestion: None known

Known Clinical Effects:
May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Symptoms of chronic exposure to tetracyclines include redness and swelling of the skin, rash, chills, tooth discoloration, yellowing of the skin and eyes, nausea, vomiting, diarrhea, stomach pain, and chest pain. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Wheezing, asthma, low or high blood pressure, dizziness, lung congestion, blood changes (leukocytosis, atypical lymphocytes, toxic granulation of granulocytes and thrombocytopenia purpura), convulsion or shock may also occur.
4. FIRST AID MEASURES

Eye Contact:  Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact:  Wash skin with soap and water. Remove contaminated clothing and shoes. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion:  Get medical attention immediately. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation:  Remove to fresh air. Get medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media:  Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products:  May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

Fire Fighting Procedures:  Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

Fire / Explosion Hazards:  Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:  Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting:  Contain the source of the spill or leak. Use non-combustible absorbent material to wipe up spill and place in a sealed container for disposal. Clean spill area thoroughly.

Measures for Environmental Protections:  Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills:  Review Sections 3, 8 and 12 before proceeding with clean up. Contain the source of the spill or leak if it is safe to do so. Dike, pump, or use non-combustible material to absorb spill; then place in a suitable, labeled recovery container. Transfer all waste to a labeled container and move it to a secure holding area. Close container and move it to a secure holding area. Clean spill area thoroughly with detergent and water. Collect wash water with a non-combustible absorbent material and transfer to labeled container for treatment and disposal.

7. HANDLING AND STORAGE

General Handling:  Use only in a well-ventilated area. Avoid contact with eyes. Avoid contact with skin and clothing. Avoid breathing vapor or mist.
Storage Conditions: Keep container tightly closed when not in use. Store out of direct sunlight in a well ventilated area at room temperature.

Storage Temperature: 15-30°C

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Oxytetracycline hydrochloride

Pfizer OEL TWA-8 Hr: 0.5 mg/m³


Engineering Controls: Good general ventilation should be sufficient to control airborne levels.

Personal Protective Equipment:

Hands: None required under normal and foreseeable conditions of use.

Eyes: Not required under normal conditions of use.

Skin: None required under normal and foreseeable conditions of use. Wash hands and arms thoroughly after handling this material.

Respiratory protection: None required under normal conditions of use. Whenever air contamination (mist, vapor or odor) is generated, respiratory protection is recommended as a precaution to minimize exposure.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Suspension

Color: Light yellow

Odor: Odorless

Molecular Formula: Mixture

Molecular Weight: Mixture

Solubility: Insoluble: Water

10. STABILITY AND REACTIVITY

Stability: Stable

Conditions to Avoid: Contact with moist air causes darkening of this material. Direct sunlight, excessive heat, sparks or open flame

Incompatible Materials: Bases, strong oxidizers

Hazardous Decomposition Products: No data available See Section 5 - under Hazardous combustion products.

Polymerization: Will not occur

11. TOXICOLOGICAL INFORMATION

NTP: Not classified

IARC: Not classified

OSHA: No

Oxytetracycline hydrochloride

Mouse Oral LD50 6696 mg/kg

Mouse SC LD50 600mg/kg

Rat SC LD50 800mg/kg
Material Name: Oxytetracycline hydrochloride and hydrocortisone acetate ophthalmic suspension
Revision date: 12-Jul-1999

**Ingestion Acute Toxicity**

The acute oral LD50 for the active ingredient is listed in the table, above. While this formulation has not been tested as a whole, it would not be expected to be toxic orally based on the amount of active ingredient it contains.

**Subchronic Effects**

Subacute and subchronic toxicity studies of oxytetracycline hydrochloride were performed in mice and rats for 14 days and 13 weeks. In the 14-day studies, no compound-related gross pathologic effects were seen in mice or rats given up to 100,000 ppm in their feed. In the 13-week studies, no compound-related gross or histopathologic effects were observed in male or female mice or in female rats given up 50,000 ppm in their diet. In male rats, fatty metamorphosis of minimal severity was observed in the liver in all treated animals.

**Chronic Effects/Carcinogenicity**

Long-term studies of oxytetracycline hydrochloride toxicity were conducted by the US National Toxicology Program (NTP) in mice at doses up to 1400 mg/kg/day and in rats at doses up to 2000 mg/kg/day. In mice, no compound-related increases in non-neoplastic or neoplastic lesions were observed in males or females. In rats, increased incidences of pheochromocytomas of the adrenal gland in males and adenomas of the pituitary gland in females were observed. Under the conditions of these 2-year studies, the US National Toxicology Program concluded that there was equivocal evidence of carcinogenicity in male and female rats but no evidence of carcinogenicity in male or female mice.

**Reproductive Effects**

For oxytetracycline, effects of oxytetracycline on fertility (litter size) and embryo- or fetotoxicity were observed in rats at subcutaneous dose of 1000 mg/kg, in rabbits at intramuscular dose of 789 mg/kg, and dogs (643 mg/kg) (no other details reported). Tetracyclines as a class are capable of crossing the placenta and causing staining of the primary teeth. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of labor (parturition) if used during the last trimester of pregnancy and may precipitate premature labor followed by difficult labor, fetal death, retained placenta, and inflammation of the uterus (metritis).

**Teratogenicity**

No increase in congenital defects was found in mice and rats treated with oxytetracycline at oral doses of 1500 and 2100 mg/kg on days 6 - 15 of gestation, respectively. In rabbits, oxytetracycline was administered intramuscularly at 41.5 mg/kg/day from days 10 to 28 of gestation. The number and percentage of partial and total resorptions were significantly increased; no effects on fetal body weight were observed. No abnormalities were found at necropsy. Developmental toxicity studies of hydrocortisone have been conducted in rats, mice, rabbits and pigs. In general, these studies have shown that hydrocortisone when administered to pregnant animals at high oral doses (> 200 mg/kg/day) can result in fetal pre- and post-implantation mortality, doses in the range of 100 - > 200 mg/kg/day can lead to malformations (cleft palate) and lower doses of 10 - 50 mg/kg/day can lead to delayed development of bones and soft tissues including endocrine tissues. Liver Reproductive system
Mutagenicity

No evidence of mutagenicity was observed in the Ames test using S. typhimurium strains in the presence or absence of metabolic activation. Oxytetracycline hydrochloride was mutagenic in mouse lymphoma cells L5178Y/TK in the presence but not in the absence of metabolic activation. It was weakly positive in inducing sister chromatid exchanges in cultured Chinese hamster ovary cells with and without metabolic activation but did not induce chromosomal aberrations.

Oxytetracycline hydrochloride

24 Month(s)  Rat  Oral, in feed  150 mg/kg/day  NOEL  Not carcinogenic
103 Week(s)  Mouse  Oral, in feed  1372 mg/kg/day  NOEL  Not carcinogenic

Carcinogen Status:

Not listed as a carcinogen by IARC, NTP or US OSHA.

At increase risk from exposure:

Individuals who have shown hypersensitivity to this material or other materials in its chemical class and individuals with liver and/or kidney dysfunction or impairment may be more susceptible to toxicity in cases of overexposure. Individuals with alcoholic liver disease and also individuals with hyperlipidemia, especially hypertriglyceridemia, may be more likely to exhibit fatty changes from tetracycline.

12. ECOLOGICAL INFORMATION

Environmental Overview:

See Aquatic toxicity data of the active ingredient, below:

Oxytetracycline hydrochloride

Rainbow Trout  LC50  > 116 mg/L

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:

Incineration is the recommended method of disposal for this material. This material may also be disposed in landfills. Observe all local and national regulations when disposing of this material.

14. TRANSPORT INFORMATION

Not regulated

Proper shipping name:

Oxytetracycline hydrochloride and hydrocortisone acetate ophthalmic suspension

15. REGULATORY INFORMATION

OSHA Label:
CAUTION
Infants of mothers exposed during pregnancy may develop discoloration of the teeth

Canada - WHMIS: Classifications

WHMIS hazard class:
EU Classification/Labelling: Not classified.

Oxytetracycline hydrochloride
   California Proposition 65 developmental toxicity, initial date 10/1/91 (internal use)
   EU EINECS List 218-161-2
   Inventory - United States TSCA - Sect. 8(b) Listed

Hydrocortisone acetate
   EU EINECS List 200-004-4

Aluminum stearate
   EU EINECS List 211-279-5
   Inventory - United States TSCA - Sect. 8(b) Listed

Mineral oil, heavy
   EU EINECS List 232-455-8
   Inventory - United States TSCA - Sect. 8(b) Listed

16. OTHER INFORMATION

Prepared by: Corporate Occupational Toxicology & Hazard Assessment

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet